- Efficient bluish green electroluminescence of iridium complexes with good electron mobility
-
Two novel iridium(iii) complexes (Ir1 and Ir2), synthesized using 2′-(trifluoromethyl)-2,5′-bipyrimidine and 5-fluoro-2′-(trifluoromethyl)-2,5′-bipyrimidine as the main ligands, and tetraphenylimidodiphosphinate (tpip) as an ancillary ligand, were investigated. The introduction of a nitrogen heterocycle and CF3 substituent improves the electron mobility of the Ir(iii) complexes, which is beneficial for device performance. Both of the complexes emit bluish green photoluminescence with very high quantum efficiency yields (Ir1: λmax: 485/516 nm, ηPL: 89%; Ir2: λmax: 482/513 nm, ηPL: 95%) and good electron mobility. Organic light-emitting diodes (OLEDs) constructed with an ITO (indium tin oxide)/MoO3 (molybdenum oxide, 3 nm)/TAPC (di-[4-(N,N-ditolyl-amino)-phenyl]cyclohexane, 50 nm)/mCP (1,3-bis(9H-carbazol-9-yl)benzene, 5 nm)/Ir complex (6 wt%):PPO21 (3-(diphenylphosphoryl)-9-(4-(diphenyl-phosphoryl)phenyl)-9H-carbazole, 10 nm)/TmPyPB (1,3,5-tri(m-pyrid-3-yl-phenyl)benzene, 50 nm)/LiF (1 nm)/Al (100 nm) structure showed good device performances. Device G1 based on Ir1 showed a ηc,max value of 62.99 cd A-1 with an EQEmax value of 23.5%. Owing to the slightly higher PL efficiency and lower LUMO levels of Ir2, which are beneficial for electron injection, the device based on Ir2 displayed a slightly better performance with a ηc,max value of 71.18 cd A-1 and an EQEmax value of 27.7%. Even at a practical brightness of 1000 cd m2, values of 57.39 cd A-1 and 22.3% could still be reached.
- Han, Hua-Bo,Wu, Zheng-Guang,Zheng, You-Xuan
-
-
Read Online
- METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES
-
Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by "a", R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.
- -
-
Paragraph 756; 757
(2018/06/21)
-
- CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME
-
A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has superior TRPA1 antagonist activity, and the compound or a pharmaceutically acceptable salt thereof is useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.
- -
-
Paragraph 0131
(2018/06/15)
-
- Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling
-
Transient receptor potential ankyrin 1 (TRPA1) is a non-selective cation channel expressed in sensory neurons where it functions as an irritant sensor for a plethora of electrophilic compounds and is implicated in pain, itch, and respiratory disease. To s
- Chen, Huifen,Volgraf, Matthew,Do, Steven,Kolesnikov, Aleksandr,Shore, Daniel G.,Verma, Vishal A.,Villemure, Elisia,Wang, Lan,Chen, Yong,Hu, Baihua,Lu, Ai-Jun,Wu, Guosheng,Xu, Xiaofeng,Yuen, Po-Wai,Zhang, Yamin,Erickson, Shawn D.,Dahl, Martin,Brotherton-Pleiss, Christine,Tay, Suzanne,Ly, Justin Q.,Murray, Lesley J.,Chen, Jun,Amm, Desiree,Lange, Wienke,Hackos, David H.,Reese, Rebecca M.,Shields, Shannon D.,Lyssikatos, Joseph P.,Safina, Brian S.,Estrada, Anthony A.
-
p. 3641 - 3659
(2018/05/01)
-
- SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO
-
Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.
- -
-
Paragraph 772; 773
(2017/01/31)
-
- HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME
-
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.
- -
-
Paragraph 0515; 0516
(2016/12/01)
-
- 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS
-
The invention is concerned with the compounds of formula I and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.
- -
-
Paragraph 0727; 0730; 0731
(2016/09/22)
-
- SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
-
The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
- -
-
Paragraph 01873; 01874
(2015/04/28)
-
